Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved the prognosis of mutant lung cancer; however, the clinical application value of TKIs for nonclassical EGFR mutation is unclear, especially for patients with rare uncommon mutations. METHODS: A retrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Teng, Wang, Shouzheng, Ying, Jianming, Wang, Yan, Hu, Xingsheng, Hao, Xuezhi, Xu, Ziyi, Xing, Puyuan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563151/
https://www.ncbi.nlm.nih.gov/pubmed/34549528
http://dx.doi.org/10.1111/1759-7714.14156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563151/
https://www.ncbi.nlm.nih.gov/pubmed/34549528
http://dx.doi.org/10.1111/1759-7714.14156

Ejemplares similares